Zvast-Bio Technical Exchange z-bo 2020-12-25 1247

　　On the morning of December 24, 2020, a team of thirteen experts headed by Yan Yaping, deputy dean of the Second Affiliated Hospital of Nanhua University, came to Zvast-Bio to inspect production, education and research. Received warm reception from general manager Jiang Bin, R&D director Dr. Yuan Yongming, and sales center director Wang Junping. The two parties conducted in-depth discussions on the topic of industry, university and research.

The topic of academic research has been discussed in depth.

　　Dean Yan and his entourage first watched the company’s corporate video. Jiang Bin, general manager of  Zvast-Bio, gave a detailed introduction on Zvast-Bio’s industry track. Zvast-Bio takes animal models as the core and takes life science and technology services and drug R&D CRO as the core. A national high-tech enterprise in the industry track. Since its establishment, Zvast-Bio has always paid attention to the transformation of scientific research results and the introduction of talents. It has formed a scientific research team led by returned doctors, obtained 17 patents, and obtained 40 trademark registration rights, and has a comprehensive experimental platform of nearly 10,000 square meters. With the "Experimental Animal Use License" issued by the Jiangxi Provincial Department of Science and Technology, the company currently has more than 150 animal models of diseases, and is a leading biotechnology service company in the domestic reserve of animal models of diseases. With the vigorous development of the domestic biopharmaceutical industry, the number of companies engaged in new drug research and development is increasing. As an important part of the industry, the CRO industry has a huge market. As a company that started with life science services, Zvast-Bio has entered the CRO field. With the launch of the domestic science and technology version, the CRO industry has also opened the curtain of listing, but there is still no obvious leading listed company in the subdivision of drug efficacy and pharmacy. In view of the strong technology of Zvast-Bio in this field And market ability, the company stands out in the industry competition, the market prospect is very broad.

　　Dean Yan and his entourage appreciated Zvast-Bio's active participation in hospital-enterprise cooperation in clinical and research in the biological field.

　　Dean Yan introduced: The Second Affiliated Hospital of Nanhua University was founded in 1949. It is the third teaching hospital in Hunan Province after the First and Second Affiliated Hospitals of Xiangya. It is an integrated medical, teaching, and scientific research hospital. Large-scale comprehensive tertiary first-class hospital. The hospital has first-class medical technology and distinctive specialties. It was the first batch to be approved by the Ministry of Health to carry out human organ transplantation qualifications. Among them, the East Hospital's Thoracic Medicine Center cooperates with Beijing Fuwai Cardiology Hospital and is the only thoracic hospital in southern Hunan. The hospital is also the earliest directly affiliated hospital of Nanhua University. It is responsible for the education and training of more than 200 graduate students every year. It is a first-level discipline master degree authorization point in clinical medicine. It became a clinical medicine doctor training unit in 2018 and started in 2019 Recruit doctoral students. In the past five years, the hospital’s scientific and technological strength has been significantly strengthened: it has undertaken more than 100 projects including the National Natural Science Foundation of China, key provincial and ministerial projects, outstanding youth funds, specialist projects, and general projects. More than 10 scientific research achievements.

Dean Yan made academic remarks.

　　The two sides agreed that science and technology are the primary productive forces, and fully promoting the transformation of scientific and technological achievements is an important way to improve scientific research efficiency and comprehensive national strength. In order to accelerate the promotion of scientific and technological strength in the field of health and the efficiency of scientific research results transformation, the optimization of the collaborative innovation mechanism has accelerated the development of the integration of industry, university, research and application. This time, the two parties will rely on existing conditions to deepen cooperation in education and teaching, scientific research, and the transformation of scientific research results, and accelerate the cultivation and transformation of scientific and technological achievements. Zvast-Bio is a national high-tech enterprise with life science technology service and drug R&D CRO as the industry track. The hospital-enterprise cooperation experience and medical scientific research results are rich; in the following cooperation, it is expected to fully learn from the experience and explore more scientific and effective paths and methods in clinical research.

　　Before the negotiation between the two parties, Dr. Yuan Yongming, Director of R&D Department, led Dean Yan and his party to visit the laboratory scientific research platform and showed the development history of Zvast-Bio.

　　Enhancing understanding in communication, deepening consensus in understanding, and unified action in consensus. Let us work together to work together and resonate at the same frequency to improve the efficiency of scientific research and make in-depth contributions to medical development, medical education and medical standards. Pay more to meet the health needs of the people!